Tempus AI's data engine, MRD buildout and ADLT milestones set the stage for faster growth while profitability metrics turn ...

We recently compiled a list of the Top 12 AI Stock News and Ratings Dominating Wall Street. In this article, we are going to take a look at where Tempus AI, Inc (NASDAQ:TEM) stands against the other ...

Collaboration extension through 2029 accelerates access to MRD technology across four major cancer types Colorectal cancer affects over 150,000 new patients in the U.S. annually, with many patients ...

Personalis (PSNL) and Tempus AI (TEM) announced that the companies have expanded their commercial relationship.The companies agreed in November 2023 to collaborate and bring ultra-sensitive MRD ...

Tempus AI TEM reported non-GAAP profit in the third quarter of 2025 as genomics testing and data services gained momentum.

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq: TEM) announced today that the companies have expanded their commercial relationship. The companies agreed ...

Tempus AI TEM posted another breakout quarter as diagnostics volumes and pricing improved while data partnerships extended ...

Tempus AI has EV/forward revenue under 10x, positive EBITDA, 33% genomics growth, and $150M in new contracts. Find out why ...

Tempus AI, Inc (NASDAQ:TEM) is a healthcare technology company that provides AI-enabled precision medicine solutions. On December 16, the company announced that it has expanded its relationship with ...

Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq: TEM) announced today that the companies have expanded their commercial relationship. The companies agreed in November 2023 to collaborate ...